News
Orforglipron: What to Know About Eli Lilly’s New Weight Loss Pill for Obesity
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.
In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
East Idaho News on MSN19h
Company hikes Mounjaro prices in the UK to make weight-loss drug cheaper in the US
Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down ...
The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...
The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...
The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...
The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback